Blair William & Co. IL raised its stake in shares of Novartis AG (NYSE:NVS) by 18.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 177,392 shares of the company’s stock after buying an additional 27,743 shares during the period. Blair William & Co. IL’s holdings in Novartis AG were worth $14,807,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the stock. Washington Trust Bank raised its position in Novartis AG by 0.3% in the second quarter. Washington Trust Bank now owns 4,384 shares of the company’s stock valued at $366,000 after buying an additional 14 shares in the last quarter. North Star Investment Management Corp. raised its stake in shares of Novartis AG by 1.0% in the second quarter. North Star Investment Management Corp. now owns 1,542 shares of the company’s stock worth $129,000 after buying an additional 16 shares during the period. Ledyard National Bank raised its stake in shares of Novartis AG by 0.9% in the second quarter. Ledyard National Bank now owns 3,428 shares of the company’s stock worth $286,000 after buying an additional 30 shares during the period. Parkside Financial Bank & Trust raised its stake in shares of Novartis AG by 0.7% in the second quarter. Parkside Financial Bank & Trust now owns 4,492 shares of the company’s stock worth $375,000 after buying an additional 31 shares during the period. Finally, Enterprise Financial Services Corp raised its stake in shares of Novartis AG by 1.7% in the second quarter. Enterprise Financial Services Corp now owns 2,579 shares of the company’s stock worth $215,000 after buying an additional 42 shares during the period. 10.97% of the stock is currently owned by institutional investors.

Shares of Novartis AG (NYSE NVS) opened at 83.62 on Wednesday. The company has a market cap of $195.91 billion, a price-to-earnings ratio of 30.53 and a beta of 0.73. Novartis AG has a 52 week low of $66.93 and a 52 week high of $86.90. The stock’s 50 day moving average is $83.94 and its 200-day moving average is $79.45.

Novartis AG (NYSE:NVS) last issued its quarterly earnings data on Tuesday, July 18th. The company reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.16 by $0.06. The firm had revenue of $12.24 billion for the quarter, compared to analyst estimates of $12.20 billion. Novartis AG had a net margin of 13.52% and a return on equity of 15.51%. Novartis AG’s revenue was down 1.8% on a year-over-year basis. During the same period in the previous year, the firm earned $1.23 EPS. On average, equities analysts anticipate that Novartis AG will post $4.74 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/08/30/blair-william-co-il-acquires-27743-shares-of-novartis-ag-nvs.html.

A number of brokerages have issued reports on NVS. Leerink Swann reissued a “market perform” rating and issued a $83.00 price target on shares of Novartis AG in a report on Thursday, June 22nd. Morgan Stanley reissued a “sell” rating on shares of Novartis AG in a report on Tuesday, June 6th. UBS AG reissued a “neutral” rating on shares of Novartis AG in a report on Wednesday, May 24th. Credit Suisse Group lowered shares of Novartis AG from a “neutral” rating to an “underperform” rating and set a $82.25 price target on the stock. in a report on Wednesday, July 5th. Finally, Cowen and Company set a $77.00 price target on shares of Novartis AG and gave the stock a “hold” rating in a report on Tuesday, July 11th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and six have given a buy rating to the stock. Novartis AG presently has a consensus rating of “Hold” and a consensus price target of $83.56.

In related news, major shareholder Bioventures Ltd Novartis acquired 266,667 shares of Novartis AG stock in a transaction that occurred on Wednesday, July 5th. The shares were purchased at an average cost of $15.00 per share, for a total transaction of $4,000,005.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.01% of the stock is currently owned by insiders.

About Novartis AG

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)

Receive News & Stock Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related stocks with our FREE daily email newsletter.